Business
ValiSeek Development Update
ValiSeek Development Update.
About this update from Valirx Plc
[{"type":"text","content":"\n \nRNS Number : 5674Q ValiRx PLC 02 September 2014 \n \n\n \n \n2 September 2014\n \nValiRx Plc\n(\"ValiRx\" or \"the Company\")\n \nValiSeek Development Update\n \n Successful completion of preclinical efficacy studies in non-small cell lung cancer\n \nValiRx Plc (AIM: VAL), the life science company with a focus on cancer diagnostics and therapeutics for personalised medicine, is pleased to provide a further development and scientific update on the progress of pre-clinical studies at ValiSeek Limited (\"ValiSeek\"), ValiRx's joint venture company with Tangent Reprofiling Limited (\"Tangent\"). \n \nValiSeek was formed to develop VAL401, the novel lung cancer treatment drug, through its remaining preclinical development and towards Clinical Efficacy (Phase II) trials for the treatment of lung cancer and potentially other oncology indications. \n \nFurther to our development update on 15 May 2014, ValiSeek now reports on the completion of the efficacy phase of pre-clinical testing for the use of VAL401 in non-small cell lung cancer. Studies demonstrated a mean response with at least a 50 per cent. reduction in the rate of tumour growth in an accepted standard cancer model. \n \nFurthermore, no adverse effects were seen during the course of the experiment, which comprised six weeks of continuous treatment at three differing dose levels. The Company believes that these positive and exciting results confirm the promise shown by the earlier reported cellular assay results. \n \nThese in vivo study results will form the foundation of a submission for scientific advice to the MHRA for its review of the planned clinical development programme for VAL401. The formulation and preliminary pre-clinical toxicology results are expected be collated and reported by the end of 2014. \n \nFurther efficacy studies will be carried out in due course to establish the potential utility of VAL401 and its broad spectrum use against solid adenocarcinoma tumours or cancers of hormone responsive glandular origin, which include prostate, breast and pancreatic cancers and other small cell lung cancers.\n ...